Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency. Gene replacement therapy holds great promise to treat DMD. Adeno-associated virus (AAV) is the leading viral vector for muscle gene therapy. However AAV has a small packaging capacity (~ 5-kb) and it cannot carry the full-length dystrophin cDNA (~12-kb). A microgene is a super-small synthetic dystrophin gene. It contains one-third of the full-length dystrophin coding sequence. Studies from many laboratories suggest that micro-dystrophin can effectively ameliorate muscle disease in dystrophin-deficient mice. Unfortunately, translation to large mammals has so far not been very successful. We recently engineered a new ?R2-15/?R18-19/?R20-23/?C microgene (abbreviated as ?R2 Dys) and tested it adult dystrophin-null dogs by single muscle injection using Y731F AAV-9. Two months later, we observed dramatic reduction of inflammation and fibrosis. Importantly, eccentric contraction-induced damage, a physiological hallmark of DMD, was significantly alleviated. Our study demonstrates for the first time that microdystrophin can treat dystrophinopathy in muscles of large mammals. Our results also suggest that the newly developed Y731F AAV-9 ?R2 Dys vector may hold great translational potential. The overarching goal of this proposal is to address key questions related to future clinical translatio. Specifically, we will pursue two aims including (1) to test the hypothesis that regional intramuscular injection can lead to persistent protection in adult dystrophic dogs. This set of studies will allow us to evaluate the feasibility of life-quality improving therapy in late-stage wheelchair-bound patients in the future; and (2) to test the hypothesis that a single intravenous injection can lead to bodywide amelioration in young dystrophic dogs. DMD affects all muscles in the body. This set of studies will allow us to determine whether systemic intervention can radically change the disease course in affected individuals. Taking together, our studies will break through major barriers in the field and provide the much-needed large animal data to guide human trials in the future.

Public Health Relevance

Duchenne muscular dystrophy (DMD) is a life threatening disease caused by mutations in the dystrophin gene. The dystrophin-deficient dog is a large animal model that displays similar muscle disease as human patients. In this study, we will test whether a newly developed micro-dystrophin gene therapy can lead to clinically meaningful improvement in dystrophic dogs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS090634-03
Application #
9325083
Study Section
Therapeutic Approaches to Genetic Diseases Study Section (TAG)
Program Officer
Nuckolls, Glen H
Project Start
2015-09-01
Project End
2020-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Missouri-Columbia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
153890272
City
Columbia
State
MO
Country
United States
Zip Code
65211
Patel, Aman; Zhao, Junling; Yue, Yongping et al. (2018) Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOS?. Skelet Muscle 8:36
Gordish-Dressman, Heather; Willmann, Raffaella; Dalle Pazze, Laura et al. (2018) ""Of Mice and Measures"": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic. J Neuromuscul Dis 5:407-417
Duan, Dongsheng (2018) Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients. Hum Gene Ther 29:733-736
Nelson, D'anna M; Lindsay, Angus; Judge, Luke M et al. (2018) Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Hum Mol Genet 27:2090-2100
Jenkins, Gregory J; Hakim, Chady H; Yang, N Nora et al. (2018) Automatic characterization of stride parameters in canines with a single wearable inertial sensor. PLoS One 13:e0198893
Nance, Michael E; Hakim, Chady H; Yang, N Nora et al. (2018) Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10:
Wasala, Nalinda B; Shin, Jin-Hong; Lai, Yi et al. (2018) Cardiac-Specific Expression of ?H2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy. Hum Gene Ther 29:737-748
Hakim, Chady H; Mijailovic, Alex; Lessa, Thais B et al. (2017) Non-invasive evaluation of muscle disease in the canine model of Duchenne muscular dystrophy by electrical impedance myography. PLoS One 12:e0173557
Wasala, Nalinda B; Yue, Yongping; Vance, Jenna et al. (2017) Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy. J Mol Cell Cardiol 102:45-52
Hakim, Chady H; Wasala, Nalinda B; Pan, Xiufang et al. (2017) A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy. Mol Ther Methods Clin Dev 6:216-230

Showing the most recent 10 out of 20 publications